US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Propanc Biopharma, Inc.

1.35

-0.8800-39.46%

Post-market: 1.34-0.0100-0.74%19:59 EDT

Volume:4.06M

Turnover:6.74M

Market Cap:4.73M

PE:-0.04

High:1.94

Open:1.93

Low:1.31

Close:2.23

52wk High:81.00

52wk Low:0.9500

Shares:3.50M

Float Shares:1.25M

Volume Ratio:0.21

T/O Rate:324.53%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-32.4560

EPS(LYR):-371.2241

ROE:-126.98%

ROA:-62.31%

PB:0.48

PE(LYR):0.00

Loading ...

Overview Company News Filings

Propanc Biopharma announces new preclinical data for PRP in PDAC

Propanc Biopharma Says PRP Cuts Pancreatic Tumor Growth by over 90% in Preclinical Models

Propanc Biopharma - Plans Phase 1B Study in 40–45 Patients with Advanced Solid Tumors, Clinical Trial Application Expected in Coming Months

THOMSON REUTERS

Propanc Biopharma - Prp Reduces Metastatic Burden in Liver and Peritoneum in Preclinical Models

THOMSON REUTERS

Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for Prp Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit

THOMSON REUTERS

Propanc Biopharma Issues 3.5 Million Restricted Shares to Executives, Directors, Service Providers

Propanc Biopharma starts finalization of clinical trial protocol for PRP study

Propanc Biopharma Plans First-in-Human Phase 1b Trial of PRP in up to 40 Advanced Solid Tumor Patients

Propanc Biopharma Plans Phase 1b Study of PRP Proenzyme Therapy in Advanced Solid Tumors

Propanc Biopharma - to File Phase 1B Clinical Trial Application for Prp in Advanced Cancer in Q4

THOMSON REUTERS

Propanc reports new preclinical data for PRP in pancreatic ductal adenocarcinoma

Propanc Biopharma Accelerates Phase 1b First-in-Human PRP Trial in Advanced Solid Tumors

Propanc Biopharma - Prp Shows Reduced Metastatic Burden in Liver and Peritoneum

THOMSON REUTERS

Propanc Biopharma - Prp Extends Median Overall Survival by over 2.5-Fold in Animal Models

THOMSON REUTERS

Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% TUMOR Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models

THOMSON REUTERS

Propanc Biopharma - to Accelerate Phase 1B First-in-Human Study in Pancreatic Cancer

THOMSON REUTERS

Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program

THOMSON REUTERS

Propanc Biopharma Files Draft Information Statement on Restricted Stock Issuances

Propanc Biopharma Names Carlo Campiciano to Board After Van Broekhoven Retirement

Propanc Biopharma Signs MOU with Avance Clinical for PRP Phase 1b Trial Delivery

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/PPCB/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PPCB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PPCB\",,,,,undefined,":{"symbol":"PPCB","market":"US","secType":"STK","nameCN":"Propanc Biopharma, Inc.","latestPrice":1.35,"timestamp":1787947200000,"preClose":2.23,"halted":0,"volume":4056907,"hourTrading":{"tag":"盘后","latestPrice":1.34,"preClose":1.35,"latestTime":"19:59 EDT","volume":171742,"amount":233336.6944,"timestamp":1787961596407,"change":-0.01,"changeRate":-0.007407,"amplitude":0.059259},"delay":0,"changeRate":-0.39461883408071746,"floatShares":1250100,"shares":3503100,"eps":-32.455997,"marketStatus":"Market Closed","change":-0.88,"latestTime":"08-28 16:00:00 EDT","open":1.93,"high":1.94,"low":1.31,"amount":6737787.0097609,"amplitude":0.282511,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-32.455997,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788163200000},"marketStatusCode":7,"adr":0,"listingDate":1743998400000,"exchange":"NASDAQ","adjPreClose":2.23,"preHourTrading":{"tag":"盘前","latestPrice":1.93,"preClose":2.23,"latestTime":"09:29 EDT","volume":426163,"amount":790519.3670285,"timestamp":1787923799094,"change":-0.3,"changeRate":-0.134529,"amplitude":0.233139},"postHourTrading":{"tag":"盘后","latestPrice":1.34,"preClose":1.35,"latestTime":"19:59 EDT","volume":171742,"amount":233336.6944,"timestamp":1787961596407,"change":-0.01,"changeRate":-0.007407,"amplitude":0.059259},"volumeRatio":0.20828084265249786},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PPCB\",,,,,undefined,":{"symbol":"PPCB","floatShares":1250100,"roa":"-62.31%","roe":"-126.98%","lyrEps":-371.224075,"volumeRatio":0.20828084265249786,"shares":3503100,"dividePrice":0,"high":1.94,"amplitude":0.282511,"preClose":2.23,"low":1.31,"week52Low":0.95,"pbRate":"0.48","week52High":81,"institutionHeld":0,"latestPrice":1.35,"eps":-32.455997,"divideRate":0,"volume":4056907,"delay":0,"ttmEps":-32.455997,"open":1.93,"prevYearClose":13.415,"prevWeekClose":1.08,"prevMonthClose":1.01,"prevQuarterClose":1.5,"fiveDayClose":1.08,"twentyDayClose":1.01,"sixtyDayClose":1.635},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PPCB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-18","symbol":"PPCB","defaultRemindTime":1779111000000,"type":"split","dateTimestamp":1779076800000,"forFactor":25,"toFactor":1,"ratio":25},{"market":"US","date":"2025-01-29","symbol":"PPCB","defaultRemindTime":1738161000000,"type":"split","dateTimestamp":1738126800000,"forFactor":60000,"toFactor":1,"ratio":60000},{"market":"US","date":"2023-05-23","symbol":"PPCB","defaultRemindTime":1684848600000,"type":"split","dateTimestamp":1684814400000,"forFactor":1000,"toFactor":1,"ratio":1000},{"market":"US","date":"2020-11-19","symbol":"PPCB","defaultRemindTime":1605796200000,"type":"split","dateTimestamp":1605762000000,"forFactor":1000,"toFactor":1,"ratio":1000},{"market":"US","date":"2019-06-24","symbol":"PPCB","type":"split","dateTimestamp":1561348800000,"forFactor":500,"toFactor":1,"ratio":500}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PPCB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PPCB\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PPCB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PPCB","date":"2026-08-28","current":-0.041595,"percent":0.20229,"low":-1.336323,"twenty":-0.28152,"median":-0.125329,"eighty":-0.041146,"high":-0.023125,"avg":-0.18284,"sd":0.194072,"marketCap":5080767},"quantilePoints":[{"date":"2025-04-04","current":-0.050633,"twenty":-0.050633,"median":-0.050633,"eighty":-0.050633,"marketCap":84546},{"date":"2025-04-07","current":-0.048332,"twenty":-0.050633,"median":-0.050633,"eighty":-0.049713,"marketCap":80703},{"date":"2025-08-22","current":-0.938461,"twenty":-0.969897,"median":-0.655598,"eighty":-0.050633,"marketCap":51812834},{"date":"2025-08-29","current":-0.721182,"twenty":-0.884372,"median":-0.710781,"eighty":-0.050633,"marketCap":39816759},{"date":"2025-09-05","current":-0.457673,"twenty":-0.820575,"median":-0.688821,"eighty":-0.213449,"marketCap":25268328},{"date":"2025-09-12","current":-0.457673,"twenty":-0.778969,"median":-0.631034,"eighty":-0.41283,"marketCap":25268328},{"date":"2025-09-19","current":-0.506214,"twenty":-0.755854,"median":-0.517772,"eighty":-0.439644,"marketCap":27948302},{"date":"2025-09-26","current":-0.418378,"twenty":-0.712861,"median":-0.510837,"eighty":-0.435021,"marketCap":23098825},{"date":"2025-10-03","current":-0.399917,"twenty":-0.699454,"median":-0.498124,"eighty":-0.407301,"marketCap":23564414},{"date":"2025-10-10","current":-0.408611,"twenty":-0.69067,"median":-0.457673,"eighty":-0.403395,"marketCap":24076684},{"date":"2025-10-17","current":-0.343407,"twenty":-0.669984,"median":-0.449583,"eighty":-0.385572,"marketCap":20234660},{"date":"2025-10-24","current":-0.321672,"twenty":-0.645772,"median":-0.432247,"eighty":-0.369488,"marketCap":18953985},{"date":"2025-10-31","current":-0.269509,"twenty":-0.610693,"median":-0.4245,"eighty":-0.343407,"marketCap":15880366},{"date":"2025-11-07","current":-0.241906,"twenty":-0.556142,"median":-0.418378,"eighty":-0.313847,"marketCap":14253909},{"date":"2025-11-14","current":-0.169965,"twenty":-0.518234,"median":-0.404264,"eighty":-0.269509,"marketCap":10014876},{"date":"2025-11-21","current":-0.174454,"twenty":-0.514536,"median":-0.397743,"eighty":-0.234995,"marketCap":11061584},{"date":"2025-11-28","current":-0.188344,"twenty":-0.512687,"median":-0.384703,"eighty":-0.189884,"marketCap":11942288},{"date":"2025-12-05","current":-0.173885,"twenty":-0.509912,"median":-0.372748,"eighty":-0.182127,"marketCap":11025501},{"date":"2025-12-12","current":-0.170028,"twenty":-0.504827,"median":-0.356448,"eighty":-0.174606,"marketCap":10780935},{"date":"2025-12-19","current":-0.151754,"twenty":-0.498818,"median":-0.343407,"eighty":-0.171335,"marketCap":9622255},{"date":"2025-12-26","current":-0.139108,"twenty":-0.496968,"median":-0.326019,"eighty":-0.170682,"marketCap":8820401},{"date":"2026-01-02","current":-0.113099,"twenty":-0.476627,"median":-0.315152,"eighty":-0.168873,"marketCap":7171266},{"date":"2026-01-09","current":-0.101254,"twenty":-0.460447,"median":-0.284723,"eighty":-0.163023,"marketCap":6420182},{"date":"2026-01-16","current":-0.074044,"twenty":-0.457673,"median":-0.262988,"eighty":-0.151375,"marketCap":4694858},{"date":"2026-01-23","current":-0.056065,"twenty":-0.453513,"median":-0.243754,"eighty":-0.138341,"marketCap":3554888},{"date":"2026-01-30","current":-0.058573,"twenty":-0.449352,"median":-0.223866,"eighty":-0.121547,"marketCap":3713923},{"date":"2026-02-06","current":-0.042554,"twenty":-0.442879,"median":-0.192195,"eighty":-0.107345,"marketCap":2698240},{"date":"2026-02-13","current":-0.048688,"twenty":-0.435021,"median":-0.182701,"eighty":-0.093848,"marketCap":3087140},{"date":"2026-02-20","current":-0.048657,"twenty":-0.431486,"median":-0.176899,"eighty":-0.077306,"marketCap":3214676},{"date":"2026-02-27","current":-0.046857,"twenty":-0.428606,"median":-0.174834,"eighty":-0.060466,"marketCap":3095731},{"date":"2026-03-06","current":-0.040376,"twenty":-0.424799,"median":-0.173681,"eighty":-0.05647,"marketCap":2667530},{"date":"2026-03-13","current":-0.029045,"twenty":-0.422077,"median":-0.17085,"eighty":-0.050499,"marketCap":1918972},{"date":"2026-03-20","current":-0.028085,"twenty":-0.419765,"median":-0.170682,"eighty":-0.048484,"marketCap":1855535},{"date":"2026-03-27","current":-0.034166,"twenty":-0.417079,"median":-0.169454,"eighty":-0.047319,"marketCap":2257270},{"date":"2026-04-02","current":-0.035336,"twenty":-0.413827,"median":-0.167383,"eighty":-0.04606,"marketCap":2334602},{"date":"2026-04-10","current":-0.031762,"twenty":-0.406872,"median":-0.16427,"eighty":-0.043866,"marketCap":2098425},{"date":"2026-04-17","current":-0.033628,"twenty":-0.399911,"median":-0.155654,"eighty":-0.041322,"marketCap":2221738},{"date":"2026-04-24","current":-0.036697,"twenty":-0.399457,"median":-0.149858,"eighty":-0.040438,"marketCap":2424475},{"date":"2026-05-01","current":-0.032141,"twenty":-0.39557,"median":-0.138149,"eighty":-0.039889,"marketCap":2123505},{"date":"2026-05-08","current":-0.029421,"twenty":-0.386441,"median":-0.123469,"eighty":-0.037064,"marketCap":1943760},{"date":"2026-05-15","current":-0.023125,"twenty":-0.382964,"median":-0.117367,"eighty":-0.035899,"marketCap":1527837},{"date":"2026-05-22","current":-0.078772,"twenty":-0.376009,"median":-0.107725,"eighty":-0.036443,"marketCap":1446323},{"date":"2026-05-29","current":-0.077406,"twenty":-0.376009,"median":-0.101254,"eighty":-0.036697,"marketCap":1421242},{"date":"2026-06-05","current":-0.075584,"twenty":-0.369488,"median":-0.094421,"eighty":-0.037013,"marketCap":1387801},{"date":"2026-06-12","current":-0.110645,"twenty":-0.369488,"median":-0.091369,"eighty":-0.037013,"marketCap":2031540},{"date":"2026-06-18","current":-0.077861,"twenty":-0.359056,"median":-0.091369,"eighty":-0.037215,"marketCap":1429602},{"date":"2026-06-26","current":-0.068755,"twenty":-0.347754,"median":-0.088611,"eighty":-0.037494,"marketCap":1262397},{"date":"2026-07-02","current":-0.178687,"twenty":-0.344276,"median":-0.088611,"eighty":-0.038576,"marketCap":3280854},{"date":"2026-07-10","current":-0.220877,"twenty":-0.343407,"median":-0.091369,"eighty":-0.03962,"marketCap":4055500},{"date":"2026-07-17","current":-0.1973,"twenty":-0.335582,"median":-0.096459,"eighty":-0.039946,"marketCap":3622609},{"date":"2026-07-24","current":-0.179928,"twenty":-0.32515,"median":-0.101254,"eighty":-0.040156,"marketCap":3303637},{"date":"2026-07-31","current":-0.129051,"twenty":-0.321672,"median":-0.106776,"eighty":-0.040305,"marketCap":2369505},{"date":"2026-08-07","current":-0.16876,"twenty":-0.316456,"median":-0.111872,"eighty":-0.040388,"marketCap":3098584},{"date":"2026-08-14","current":-0.151387,"twenty":-0.306023,"median":-0.120497,"eighty":-0.04047,"marketCap":2779612},{"date":"2026-08-21","current":-0.136497,"twenty":-0.295156,"median":-0.123158,"eighty":-0.040781,"marketCap":2506208},{"date":"2026-08-28","current":-0.276716,"twenty":-0.28152,"median":-0.125329,"eighty":-0.041146,"marketCap":5080767}],"updateTime":1788112850844},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PPCB\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662700133","title":"Propanc Biopharma announces new preclinical data for PRP in PDAC","url":"https://stock-news.laohu8.com/highlight/detail?id=2662700133","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662700133?lang=en_us&edition=fundamental","pubTime":"2026-08-27 20:45","pubTimestamp":1787834733,"startTime":"0","endTime":"0","summary":"Propanc Biopharma (PPCB) announced new preclinical and early translational data for PRP in pancreatic ductal adenocarcinoma, or PDAC. In orthotopic...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/propanc-biopharma-announces-new-preclinical-data-for-prp-in-pdac-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/propanc-biopharma-announces-new-preclinical-data-for-prp-in-pdac-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662707660","title":"Propanc Biopharma Says PRP Cuts Pancreatic Tumor Growth by over 90% in Preclinical Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2662707660","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662707660?lang=en_us&edition=fundamental","pubTime":"2026-08-27 20:30","pubTimestamp":1787833847,"startTime":"0","endTime":"0","summary":"Propanc Biopharma says PRP cuts pancreatic tumor growth by over 90% in preclinical modelsPropanc reported new preclinical PDAC data for PRP showing >90% mean tumor growth inhibition versus vehicle con","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL9Rq3jF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","IE00BKPKM429.USD","PPCB","SG9999014039.USD","LU2095319765.USD","IE00BN0W2W23.USD","IE00BQXX3C00.GBP","SG9999014005.SGD","IE00BQXX3D17.EUR","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","LU0314104364.USD","BK4585","LU2210150020.SGD","SG9999014021.USD","SG9999014013.SGD","IE00BQXX3F31.USD","NDAQ","BCDF","IE00BN0W2T93.GBP","BK4112","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662707678","title":"Propanc Biopharma - Plans Phase 1B Study in 40–45 Patients with Advanced Solid Tumors, Clinical Trial Application Expected in Coming Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2662707678","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662707678?lang=en_us&edition=fundamental","pubTime":"2026-08-27 20:30","pubTimestamp":1787833801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUA2FVT49:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662707658","title":"Propanc Biopharma - Prp Reduces Metastatic Burden in Liver and Peritoneum in Preclinical Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2662707658","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662707658?lang=en_us&edition=fundamental","pubTime":"2026-08-27 20:30","pubTimestamp":1787833801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUA2FVT49:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662070763","title":"Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for Prp Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit","url":"https://stock-news.laohu8.com/highlight/detail?id=2662070763","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662070763?lang=en_us&edition=fundamental","pubTime":"2026-08-27 20:30","pubTimestamp":1787833801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nTUA2FVT49:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661261985","title":"Propanc Biopharma Issues 3.5 Million Restricted Shares to Executives, Directors, Service Providers","url":"https://stock-news.laohu8.com/highlight/detail?id=2661261985","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661261985?lang=en_us&edition=fundamental","pubTime":"2026-08-21 18:01","pubTimestamp":1787306484,"startTime":"0","endTime":"0","summary":"Propanc Biopharma issues 3.5 million restricted shares to executives, directors, service providersPropanc Biopharma board resolutions dated July 24, 2026 were executed via majority shareholder written","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL85S1XF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660608394","title":"Propanc Biopharma starts finalization of clinical trial protocol for PRP study","url":"https://stock-news.laohu8.com/highlight/detail?id=2660608394","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660608394?lang=en_us&edition=fundamental","pubTime":"2026-08-18 20:50","pubTimestamp":1787057418,"startTime":"0","endTime":"0","summary":"Propanc Biopharma (PPCB) announced it has commenced finalization of a clinical trial protocol and will conduct a feasibility assessment for its fir...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/propanc-biopharma-starts-finalization-of-clinical-trial-protocol-for-prp-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/propanc-biopharma-starts-finalization-of-clinical-trial-protocol-for-prp-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","IDNA","NVIB","BK4139","HYLG","GDOC","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660446786","title":"Propanc Biopharma Plans First-in-Human Phase 1b Trial of PRP in up to 40 Advanced Solid Tumor Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2660446786","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660446786?lang=en_us&edition=fundamental","pubTime":"2026-08-18 20:32","pubTimestamp":1787056337,"startTime":"0","endTime":"0","summary":"Propanc Biopharma plans first-in-human Phase 1b trial of PRP in up to 40 advanced solid tumor patientsPropanc Biopharma began finalizing plans for a first-in-human Phase 1b study of PRP in up to 40 ad","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDL7Y8rDm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B64PRP62.GBP","IE00BQXX3D17.EUR","IE00BN0W2W23.USD","BK4585","LU2210150020.SGD","BK4588","LU2210149790.SGD","BK4112","BCDF","IE00BQXX3F31.USD","NDAQ","BK4139","SG9999014005.SGD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","IE00BQXX3C00.GBP","PPCB","LU0314104364.USD","LU2095319765.USD","SG9999014013.SGD","SG9999014021.USD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658397776","title":"Propanc Biopharma Plans Phase 1b Study of PRP Proenzyme Therapy in Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2658397776","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658397776?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:46","pubTimestamp":1786538783,"startTime":"0","endTime":"0","summary":"Propanc Biopharma plans Phase 1b study of PRP proenzyme therapy in advanced solid tumorsPropanc outlined PRP, a once-weekly IV combination of trypsinogen and chymotrypsinogen, as a differentiation-bas","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL1QJjyz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658779079","title":"Propanc Biopharma - to File Phase 1B Clinical Trial Application for Prp in Advanced Cancer in Q4","url":"https://stock-news.laohu8.com/highlight/detail?id=2658779079","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658779079?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:36","pubTimestamp":1786538212,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4490OW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657163740","title":"Propanc reports new preclinical data for PRP in pancreatic ductal adenocarcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2657163740","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657163740?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:51","pubTimestamp":1786024283,"startTime":"0","endTime":"0","summary":"Propanc Biopharma (PPCB) announced new preclinical and translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma, one of th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/propanc-reports-new-preclinical-data-for-prp-in-pancreatic-ductal-adenocarcinoma-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/propanc-reports-new-preclinical-data-for-prp-in-pancreatic-ductal-adenocarcinoma-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657363163","title":"Propanc Biopharma Accelerates Phase 1b First-in-Human PRP Trial in Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2657363163","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657363163?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:36","pubTimestamp":1786019818,"startTime":"0","endTime":"0","summary":"Propanc Biopharma accelerates Phase 1b first-in-human PRP trial in advanced solid tumorsPropanc Biopharma on Aug. 6, 2026 flagged new preclinical, early translational PRP data in pancreatic cancer mod","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL117tCQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657631800","title":"Propanc Biopharma - Prp Shows Reduced Metastatic Burden in Liver and Peritoneum","url":"https://stock-news.laohu8.com/highlight/detail?id=2657631800","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657631800?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:31","pubTimestamp":1786019499,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN44319K:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657631388","title":"Propanc Biopharma - Prp Extends Median Overall Survival by over 2.5-Fold in Animal Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2657631388","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657631388?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:31","pubTimestamp":1786019499,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN44319K:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657386631","title":"Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% TUMOR Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2657386631","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657386631?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:31","pubTimestamp":1786019499,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN44319K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657313516","title":"Propanc Biopharma - to Accelerate Phase 1B First-in-Human Study in Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2657313516","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657313516?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:31","pubTimestamp":1786019499,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN44319K:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657440135","title":"Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2657440135","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657440135?lang=en_us&edition=fundamental","pubTime":"2026-08-05 20:30","pubTimestamp":1785933000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nTUA9YSQLR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PPCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657510441","title":"Propanc Biopharma Files Draft Information Statement on Restricted Stock Issuances","url":"https://stock-news.laohu8.com/highlight/detail?id=2657510441","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657510441?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:00","pubTimestamp":1785924059,"startTime":"0","endTime":"0","summary":"Propanc Biopharma files draft information statement on restricted stock issuancesPropanc Biopharma shareholders authorized new restricted common stock issuances totaling 3.5 million shares for officer","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL4bhhmH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPCB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651486063","title":"Propanc Biopharma Names Carlo Campiciano to Board After Van Broekhoven Retirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2651486063","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651486063?lang=en_us&edition=fundamental","pubTime":"2026-07-15 04:02","pubTimestamp":1784059336,"startTime":"0","endTime":"0","summary":"Propanc Biopharma names Carlo Campiciano to board after Van Broekhoven retirementPropanc Biopharma reported a board change effective July 8, 2026, with director Annie Van Broekhoven retiring and stepp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nNDLX4K6t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7094","PPCB","AHE.AU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649980618","title":"Propanc Biopharma Signs MOU with Avance Clinical for PRP Phase 1b Trial Delivery","url":"https://stock-news.laohu8.com/highlight/detail?id=2649980618","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649980618?lang=en_us&edition=fundamental","pubTime":"2026-07-07 20:33","pubTimestamp":1783427581,"startTime":"0","endTime":"0","summary":"Propanc Biopharma signs MOU with Avance Clinical for PRP Phase 1b trial deliveryPropanc Biopharma signed an MOU with Avance Clinical to support clinical delivery of its Phase 1b first-in-human trial o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nNDL7HSY8D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","LU2210149790.SGD","SG9999014005.SGD","SG9999014013.SGD","NDAQ","IE00BGHQF748.EUR","LU0314104364.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","LU2210150020.SGD","LU2095319765.USD","PPCB","BK4585","IE00BN0W2W23.USD","BK4139","BK4588","SG9999014021.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4112","IE00B3QW5Z07.USD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":60,"code":"91000000","status":"200"}]}}